Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vumerity

- PMLiVE

BeiGene’s Brukinsa receives CHMP recommendation for chronic lymphocytic leukaemia

CLL accounts for around one-quarter of new leukaemia cases

- PMLiVE

Biogen doses first patient with litifilimab in cutaneous lupus erythematosus study

The phase 2/3 study is expected to be conducted at approximately 238 sites worldwide

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

- PMLiVE

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

Results from the phase 3 trial showed reduction in clinical decline

Biogen Idec building

Biogen to pay $900m to settle whistleblower’s MS drug kickback lawsuit

For pursuing the case, the former employee will receive about $250m

- PMLiVE

Biogen’s tofersen shows promise in rare form of ALS in new data analysis

Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster receives CHMP recommendation

If an authorisation is granted, doses of the bivalent booster will be available to all 27 EU member states

- PMLiVE

Sanofi halts recruitment for trials assessing MS treatment

The pause in enrolment follows advice issued by the Independent Data Monitoring Committee

- PMLiVE

Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer’s disease

Eisai presented the data at the Alzheimer’s Association International Conference (AAIC)

- PMLiVE

Positive results for Biogen’s lupus drug published in NEJM

Around 90% of people with lupus are women, a condition for which there is currently no cure

- PMLiVE

FDA grants priority review to Biogen’s tofersen for genetic form of ALS

The approval follows a failed phase 3 study, but the treatment showed promise in patients with SOD1-ALS

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma

If approved by the EC, Opdualag would be the first LAG-3 blocking antibody combination available in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links